Department of Gynecologic Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Mod Pathol. 2022 Jun;35(6):786-793. doi: 10.1038/s41379-021-00979-4. Epub 2021 Nov 30.
The role of programmed cell death-ligand 1 (PD-L1) in cervical cancer has been widely investigated; however, the influences of other inhibitory B7 family members are poorly understood. We investigated the expression of PD-L1, B7 homolog 3 (B7-H3), B7-H4, and V-domain Ig suppressor of T-cell activation (VISTA) and their association with the clinicopathological features and outcomes of a large cohort of 673 patients with squamous cell carcinoma or adenocarcinoma of the uterine cervix. The positivity rates for PD-L1 (combined positive score ≥1), B7-H3 in tumor cells (TCs), B7-H4 (exclusively in TCs), VISTA in immune cells (ICs), and VISTA in TCs were 57.9%, 62.8%, 44.8%, 92.6%, and 4.8%, respectively, in 606 primary cervical cancer samples. Co-expression of PD-L1 with B7-H3 in TCs and with B7-H4 and VISTA in ICs was observed in 38.8%, 25.4%, and 57.9% of samples, respectively. B7-H3 in TCs and B7-H4 and VISTA in ICs were observed in 58.1%, 46.6%, and 83.1% of PD-L1-negative samples, respectively. These proteins were observed more frequently in squamous cell carcinomas and in moderately to poorly differentiated carcinomas. VISTA (in ICs) and B7-H4 were more frequent in primary tumors than in recurrent counterparts and correlated with improved survival; in contrast, B7-H3 positivity in TCs was less frequent in primary tumors and correlated with short disease-specific survival. Co-expression of B7-H4 and VISTA in ICs was an independent predictor of favorable outcomes overall and among patients with PD-L1-negative tumors. These data indicate that B7 family proteins exhibit differing expression patterns, distributions, and prognostic implications in cervical cancer. Furthermore, the co-expression of PD-L1 with other checkpoint proteins suggests that PD-1/PD-L1 blockade combined with modulating other immune checkpoints may present a novel therapeutic approach for cervical cancer. Future studies are needed to validate prognostic values of B7 family proteins and explore their biological roles in this malignancy.
程序性细胞死亡配体 1(PD-L1)在宫颈癌中的作用已得到广泛研究;然而,其他抑制性 B7 家族成员的影响尚不清楚。我们研究了 PD-L1、B7 同源物 3(B7-H3)、B7-H4 和 T 细胞激活的 V 域免疫球蛋白抑制剂(VISTA)在 673 例宫颈鳞状细胞癌或腺癌患者的大队列中的表达及其与临床病理特征和结局的关系。在 606 例原发性宫颈癌样本中,PD-L1(组合阳性评分≥1)、肿瘤细胞(TCs)中的 B7-H3、TCs 中仅有的 B7-H4、免疫细胞(ICs)中的 VISTA 和 TCs 中的 VISTA 的阳性率分别为 57.9%、62.8%、44.8%、92.6%和 4.8%。在 38.8%、25.4%和 57.9%的样本中分别观察到 PD-L1 与 TCs 中的 B7-H3 和 ICs 中的 B7-H4 和 VISTA 的共表达。在 58.1%、46.6%和 83.1%的 PD-L1 阴性样本中分别观察到 TCs 中的 B7-H3 和 ICs 中的 B7-H4 和 VISTA。这些蛋白在鳞状细胞癌和中-低分化癌中更为常见。与原发性肿瘤相比,VISTA(ICs)和 B7-H4 在复发性肿瘤中更为常见,与生存改善相关;相反,TCs 中 B7-H3 的阳性率在原发性肿瘤中较低,与疾病特异性生存时间短相关。ICs 中 B7-H4 和 VISTA 的共表达是总体和 PD-L1 阴性肿瘤患者预后良好的独立预测因素。这些数据表明,B7 家族蛋白在宫颈癌中表现出不同的表达模式、分布和预后意义。此外,PD-L1 与其他检查点蛋白的共表达表明,PD-1/PD-L1 阻断联合调节其他免疫检查点可能为宫颈癌提供一种新的治疗方法。需要进一步的研究来验证 B7 家族蛋白的预后价值,并探索它们在这种恶性肿瘤中的生物学作用。